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SUMMARY
Bleomycin is an antitumor antibiotic, which is used among others in
the treatment of patients with disseminated testicular cancer. Its lack
of myelosuppression makes bleomycin appropriate for combination
chemotherapy schedules. The dose-limiting side effect of bleomycin is
the pulmonary tox ic i ty .
Because of the improved results in the treatment of patients with dis-
seminated testicular cancer, the quality of l i fe of these patients is to an
important degree determined by the side effects of the cytostatic drugs.
Studies of these side effects are therefore relevant.
The studies, described in this thesis, were carried out in a group of
patients with disseminated testicular cancer. All patients were treated
with bleomycin for 12 weeks, in a dosage of 30 mg once a week, injected
intravenously, and two other cytostatic drugs without pulmonary toxi-
city, namely cis-diammine-dichloro platinum and vinblastine.
The following questions were formulated in chapter I:
1. What is the value of pulmonary function tests in detecting and moni-
toring (sub-)clinical bleomycin toxicity?
2. What influence does renal function have on the pulmonary toxicity
of bleomycin?
3. Is it possible to predict the occurrence of bleomycin-induced pneu-
moni t is  (BIP)?
4. What is the meaning of a decreased pretreatment value of the spiro-
metry, the transfer factor of the lungs for carbon monoxyde (TICO)
and its components?
5. Is there a degree of reversibil i ty of the bleomycin-induced changes
in lung function parameters?
A review of the l iterature concerning bleomycin is given in chapter
II. It is known that bleomycin can induce an interstit ial pneumonitis in
animals and men. Investigations into the role several examinations play
in the detection and monitoring of the bleomycin-induced damage are
discussed. Risk factors in the occurrence of BIP are given. Results of
investigations into the prevention and treatment of BIP and bleomycin
analogues are also discussed.
In chapter III the lung function tests, used in all studies, are descri-
bed.
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In chapter IV the changes in spirometry, TICO, the diffusing capacity
of the alveolo-capil lary membrane (Dm) and the pulmonary capil lary
blood volume (Vc) are described. Two groups of patients could be dis-
criminated. One group without (I) and one group with (II) cl inical signs
and symptoms of BIP. It was found that no changes in the slow inspira-
tory vital capacity (VC) and VA were present in group I during the re-
mission induction of twelve weeks and the ensuing observation period
of 42 weeks. In this group TICO decreased in the second part of the
observation period. The same was found in Dm, but to a greater de-
gree. Vc decreased during the remission induction, but returned to pre-
treatment values in the observation period in this group. We found a
decrease in VC and VA, that disappeared during the follow-up period.
The decrease of TICO and Dm started earlier and occurred to a greater
degree in group II. The decrease of Vc was less pronounced in this
group, but the increase of Vc above the pretreatment value during the
observation period was striking.
'I 'hese 
results demonstrate TICO to be less sensitive in monitoring
bleomycin-induced pulmonary toxicity than its two components Dm
and Vc. It is suggested that the init ial endothelial damage may be ex-
pressed by the decrease of Vc and the ensuing fibrosis can possibly be
measured by Dm. The increase of Vc may act as a compensation me-
chanism for the reduced Dm, and in this way to a smaller reduction of
TICO.
In chapter V the relationship between renal function and pulmonary
function is described. This investigation was carried out because the
CDDP can lead to a decrease of renal function and in this way to a de-
creased clearance of bleomycin which can possibly cause an increased
risk of pulmonary toxicity. The glomerular f i l tration rate (GFR), the
effective renal plasma flow (ERPF), the spirometry and the TICO were
measured before the start of any therapy and at the end of the remission
induction in 18 patients. A relationship between the change in GFR and
the change in TICO was found. No relationship could be demonstrated
between the other investigated parameters. It was concluded that a
CDDP-induced renal function impairment increases the risk of bleo-
mycin-induced pulmonary toxicity.
The results of the investigation carried out to demonstrate which pa-
rameters are valuable in predicting BIP are described in chapter VL
Spirometry, TICO, Dm, Vc and creatinine clearance were measured in
39 patients. Eight of these 39 patients developed BIP. After performing
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discriminate analysis, it was concluded that patients with a low-normal
creatinine clearance in combination with a decrease in VC and VA.
without a change of Vc run an increased risk of developing BIP. It is
advised to monitor these parameters during therapy.
The meaning of an abnormal pretreatment TICO, Dm or Vc is
described in chapter VII. It was found that a subgroup of patients with
a low Vc could be discriminated before the start of the therapy. There
were no differences anymore between this subgroup and the other pa-
tients at the end of the study period. The risk of BIP was not increased
in the patients with a decreased pretreatment Vc, therefore no reduc-
tion of the dose of bleomycin seemed indicated in this subgroup. This
decreased pretreatment Vc can possibly be explained by tumor embo-
l ism.
The natural course of BIP is described in chapter VIII. It was found
that patients had no pulmonary signs and symptoms two years after
BIP. Chest radiographs also showed no abnormalit ies anymore. Pul-
monary function tests had all normalised. Other investigations such as
technetium perfusion scan and Xenon ventilation perfusion scan simi-
larly showed no abnormalit ies two years after BIP. The broncho-alveo-
lar lavage (BAL) was performed to find out if different forms of BIP
could be demonstrated. BAL was carried out in three patients when
they were suffering from BIP and showed divergent changes in the dif-
ferentiation of the total cell amount. It can be concluded that there is
a complete reversibil i ty of all parameters in patients with BIP and that
the value of BAL is unclear, but that further investigations are indica-
ted.
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